The site is temporarily down due to maintenance. Sorry for the inconvenience.
The site is temporarily down due to maintenance. Sorry for the inconvenience.
Quality & Accuracy
Experience
The latest technologies
Speed &
Credibility
₾1,900.00 Original price was: ₾1,900.00.₾1,230.00Current price is: ₾1,230.00.
Sampling for research will be done:
Samples will be shipped on Thursday afternoons! For this, the sample must be at the central laboratory by 12:00 on Thursday
The taken sample is sent and the research is conducted in the laboratory At MEDICOVER Genetics, which is an internationally accredited laboratory.
Test results are available within 14 working days of sampling. The answer will be sent to the E-mail address of the doctor and the patient. at the post office. It is also possible to receive on-site laboratory center.
If necessary, Synevo Laboratory offers a consultation with a geneticist.
VERAgene The test is a new generation non-invasive prenatal test (NIPT) that screens for 13th (Patau syndrome), 18th (Edwards syndrome) and 21st (Down syndrome) trisomies, X, Y chromosome aneuploidy, microdeletions (DiGeorge , 1p36, Smith-Magenis, Wolf Hirschhorn) and the risk of developing 100 monogenic fetal diseases.
VERAgene The test targets 2,000 mutations to detect 100 monogenic diseases. Along with screening for monogenic diseases, the possibility of simultaneous detection of aneuploidies and microdeletions gives us a complex picture of pregnancy using a single test.
VERAgeneGenetic disorders identified by - are often serious and have a significant impact on quality of life. These genetic diseases are manifested in the form of congenital malformations, developmental delays, hearing impairment, blindness, metabolic disorders, etc.
VERAgene The cumulative risk of fetal damage by one of the genetic disorders detected by the test is 1 in every 350 pregnant women and may increase in some ethnic populations where certain diseases have a higher prevalence.
VERAgene The test can accurately identify the risk of developing these disorders and help parents make informed decisions about possible treatment and clinical management in a timely manner.
The circulating free DNA of the fetus, the so-called fetal fraction, makes up about 3-13% of the total free DNA and is mainly generated from the placenta, which disappears from the mother's blood within a few hours of the fetus's birth. The VERAgene test uses the free DNA (fetal fraction) of the fetus isolated from the mother's blood and a DNA sample taken from the biological father to determine the potential for certain genetic mutations using the latest patented technology and bioinformatics.
VERAgene The test can be performed in singleton, twin and in vitro fertilization (IVF) pregnancies from at least the 10th week of gestation. In the presence of vanishing twin syndrome, a twin pregnancy can be tested after the 10th week of gestation and 4 weeks after the disappearance of one of the embryos. Aneuploidies of X and Y chromosomes are not detected in twin pregnancy and vanishing twin syndrome.
*Sampling takes place after 4 weeks; *** Aneuploidy X, Y, Not made twins and extinct twins during pregnancy.
∨ - The test is done
Non-invasive screening avoids the risk of miscarriage and intrauterine infection, which may be associated with invasive prenatal testing (amniocentesis or chorionic biopsy). also, Timely detection of fetal aneuploidies allows for early intervention and management.
Abnormalities detected during pregnancy:
Family history of congenital anomalies.
In-vitro fertilization.
Patients with contraindications to invasive methods of prenatal diagnostics.
VERAgene The test can be performed from the 10th week of pregnancy. A doctor-specialist needs information about a detailed ultrasound examination, which will estimate the age of pregnancy (weeks), which is especially important in the early stages of pregnancy.
VERAgene Before taking the test sample, it is necessary for the patient to get acquainted with and fill in the relevant documentation, which includes: 1. Information about the sample (SIF); 2. Informed consent of the patient; 3. Information on personal data processing (including information on non-invasive prenatal testing and its limitations).
VERAgene For the test, only the venous blood of the pregnant woman and the buccal (taken from the buccal mucosa) smear of the biological father are needed. Before taking the test, a pregnant woman does not need any special preparation (fasting, etc.). As for the father - 30 minutes before taking the smear, it is recommended not to eat, smoke, or chew gum.
Due to the special characteristics of the sampling system (so-called "kits"), the analysis will be done only in "Synevo" laboratory centers or in specialized clinics, where the medical staff has been previously trained by "Synevo"
Limitations and inaccuracies:
If a pregnant woman has undergone blood transfusions, organ transplants, or stem cell therapy, there is a possibility of obtaining a false result due to the presence of exogenous DNA.
VERAgene The test can assess the following chromosomal abnormalities:
Trisomy 13 (Pataw), 18 (Edwards), 21 (Down)
Down, Edwards and Patau syndrome are genetic conditions caused by the presence of an extra chromosome (trisomy). Additional copies of chromosome 21 are responsible for Down syndrome, and additional copies of chromosomes 18 and 13 are responsible for Edwards and Patau syndrome, respectively.
Down syndrome is characterized by a decrease in the level of intellectual development and congenital defects. The incidence of the syndrome is 1 in every 700 pregnancies and is more common in women over the age of 35.
Edwards and Patau syndromes are rarer and occur in 1 in 3,000 pregnancies and 1 in 10,000 pregnancies.
The congenital defects here are so severe that children with the disease usually die in the first year of life.
Determination of sex (presence of Y-chromosome)
Aneuploidy X, Y, which includes: Turner syndrome – monosomy X0; triple X syndrome – XXX; Klinefelter's syndrome – XXY; Jacobs syndrome – XYY.
Sex chromosome aneuploidy is a genetic disorder caused by the presence or absence of a specific sex chromosome. The pair on chromosome 23 determines the sex of an individual. Women have two X chromosomes and men have one X chromosome and one Y chromosome.
There are four major sex chromosome aneuploids:
Microdelation, which includes: Dee George (22q11.2); 1p36 deletion; Smith-Mageni (17p11.2); Wolff-Hirshorn (4p16.3) syndromes.
Microdeletion is a genetic disorder caused by the loss of a specific part of a chromosome. Microdeletion is manifested in the form of various congenital anomalies and limitations of mental development. The severity of symptoms depends on the size and location of the microdeletion. The most common microdeletion syndrome is DiGeorge / DiGeorge Syndrome / Syndrome, which occurs in about every 1000 pregnancies.
100 monogenic diseases
VERAgene screens more than 2 mutations responsible for the development of 000 monogenic diseases:
A complete list of monogenic diseases detected by VERAgene can be found here:
The accuracy rate for detecting these anomalies is close but not equal to 100%.
"High risk" (positive) result For a given genetic condition, it indicates that there is a high probability (> 99.9%) that the fetus will be diagnosed with this genetic disease.
Because VERAgene is not a diagnostic test, a positive result should be confirmed by a prenatal diagnostic test of amniotic fluid or chorionic villus sampling (amniocentesis; chorion biopsy).
Although the rate of detection of genetic disorders by the test is very high.
"Low risk" (negative) result Can not completely rule out the possibility of developing genetic disorders in the fetus.
The accuracy of the test for the detection of sex chromosome aneuploids is 99.9%.
"Synevo" recommends that you get detailed information about these syndromes from a specialist doctor.
VERAgene test does not reveal:
Other tests
Testing process
Purchase a test |
Submission of material |
Results Online |
Consult a doctor |
More than 1000 routine and complex/specific diagnostic tests in all major areas of clinical pathology.
55 laboratory centers in 27 cities of Georgia: Tbilisi, Rustavi, Kutaisi, Batumi, Marneuli, Telavi, Zugdidi, Zestaponi, Gori, Kobuleti, Akhaltsikhe, Khashuri, Sartichala, Kazbegi, Borjomi, Samtredia, Gurjaani, Lagodekhi, Akhmeta, Ozurgeti, Poti, Chiatura, Kabali village, Dusheti, Kareli, Tianeti, Senaki, Lanchkhuti.
Use the Synevo web platform to view results from anywhere and anytime
Use the Synevo web platform to view results from anywhere, anytime
From Monday to Saturday you can use the laboratory services at home.
☎️ Hotline: 239 38 33 or 239 40 65
577293008 (9:00-დან 17:00-მდე)
30 laboratory centers in 11 cities of Georgia: Tbilisi, Kutaisi, Batumi, Kobuleti, Zugdidi, Zestaponi, Rustavi, Marneuli, Akhaltsikhe, Telavi, Gori.
More than 3000 routine and complex / specific diagnostic tests in all major areas of clinical pathology.
"Synevo" - Providing a wide range of diagnostic services in Georgia, offering more than 1,000 routine and specific diagnostic tests in all major areas of clinical pathology. By the end of 2024, the Synevo Georgia network will include 3 clinical laboratories and 53 blood sampling units, which will perform more than 300,000 tests.
Contact information
Address: Tsinandali St. N9 (N1 Clinical Hospital area)
2021 – 2024 © Synevo. all rights reserved